BR112021004938A2 - métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3 - Google Patents
métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3 Download PDFInfo
- Publication number
- BR112021004938A2 BR112021004938A2 BR112021004938-0A BR112021004938A BR112021004938A2 BR 112021004938 A2 BR112021004938 A2 BR 112021004938A2 BR 112021004938 A BR112021004938 A BR 112021004938A BR 112021004938 A2 BR112021004938 A2 BR 112021004938A2
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- optionally substituted
- group
- residues selected
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737017P | 2018-09-26 | 2018-09-26 | |
| US62/737,017 | 2018-09-26 | ||
| PCT/US2019/052995 WO2020069008A1 (en) | 2018-09-26 | 2019-09-25 | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021004938A2 true BR112021004938A2 (pt) | 2021-06-01 |
Family
ID=69953286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021004938-0A BR112021004938A2 (pt) | 2018-09-26 | 2019-09-25 | métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3856195A4 (de) |
| JP (1) | JP2022502441A (de) |
| KR (1) | KR20210065950A (de) |
| CN (1) | CN112789044A (de) |
| AU (1) | AU2019346456A1 (de) |
| BR (1) | BR112021004938A2 (de) |
| CA (1) | CA3111433A1 (de) |
| CL (1) | CL2021000724A1 (de) |
| CO (1) | CO2021003713A2 (de) |
| EA (1) | EA202190463A1 (de) |
| IL (1) | IL281578A (de) |
| MA (1) | MA53743A (de) |
| MX (1) | MX2021002967A (de) |
| SG (1) | SG11202102105VA (de) |
| TW (1) | TW202027752A (de) |
| WO (1) | WO2020069008A1 (de) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200538098A (en) * | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
| EP1996551A2 (de) * | 2006-03-07 | 2008-12-03 | AstraZeneca AB | Piperidinderivate, verfahren zu ihrer herstellung, ihre verwendung als therapeutische mittel und pharmazeutische zusammensetzungen, die sie enthalten |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| HUE038507T2 (hu) * | 2009-04-22 | 2018-10-29 | Sma Therapeutics Inc | 2,5-diszubsztituált arilszulfonamid CCR3-antagonisták |
| US20160208011A1 (en) * | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| AU2018248425B2 (en) * | 2017-04-05 | 2024-03-28 | Alkahest Inc. | Methods and compositions for treating retina-associated disease using CCR3-inhibitors |
| BR112019020798A2 (pt) * | 2017-04-05 | 2020-04-28 | Alkahest Inc | métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3 |
-
2019
- 2019-09-25 BR BR112021004938-0A patent/BR112021004938A2/pt not_active Application Discontinuation
- 2019-09-25 AU AU2019346456A patent/AU2019346456A1/en not_active Abandoned
- 2019-09-25 WO PCT/US2019/052995 patent/WO2020069008A1/en active Application Filing
- 2019-09-25 EP EP19867321.2A patent/EP3856195A4/de active Pending
- 2019-09-25 EA EA202190463A patent/EA202190463A1/ru unknown
- 2019-09-25 JP JP2021517342A patent/JP2022502441A/ja active Pending
- 2019-09-25 KR KR1020217008493A patent/KR20210065950A/ko unknown
- 2019-09-25 MA MA053743A patent/MA53743A/fr unknown
- 2019-09-25 SG SG11202102105VA patent/SG11202102105VA/en unknown
- 2019-09-25 MX MX2021002967A patent/MX2021002967A/es unknown
- 2019-09-25 CN CN201980063258.7A patent/CN112789044A/zh active Pending
- 2019-09-25 CA CA3111433A patent/CA3111433A1/en active Pending
- 2019-09-26 TW TW108134938A patent/TW202027752A/zh unknown
-
2021
- 2021-03-17 IL IL281578A patent/IL281578A/en unknown
- 2021-03-23 CL CL2021000724A patent/CL2021000724A1/es unknown
- 2021-03-24 CO CONC2021/0003713A patent/CO2021003713A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022502441A (ja) | 2022-01-11 |
| CA3111433A1 (en) | 2020-04-02 |
| EA202190463A1 (ru) | 2021-06-29 |
| EP3856195A1 (de) | 2021-08-04 |
| WO2020069008A1 (en) | 2020-04-02 |
| EP3856195A4 (de) | 2022-06-22 |
| CO2021003713A2 (es) | 2021-04-08 |
| MX2021002967A (es) | 2021-08-11 |
| CL2021000724A1 (es) | 2021-10-15 |
| AU2019346456A1 (en) | 2021-04-15 |
| IL281578A (en) | 2021-05-31 |
| MA53743A (fr) | 2022-01-05 |
| SG11202102105VA (en) | 2021-04-29 |
| KR20210065950A (ko) | 2021-06-04 |
| CN112789044A (zh) | 2021-05-11 |
| TW202027752A (zh) | 2020-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI791507B (zh) | 使用ccr3-抑制劑治療老化相關損傷之方法及組合物 | |
| ES2938546T3 (es) | Método de tratamiento de la esclerosis lateral amiotrófica con pridopidina | |
| JP6838085B2 (ja) | Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法 | |
| ES2824552T3 (es) | Método de tratamiento con tradipitant | |
| TW201720439A (zh) | 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物 | |
| BR112014022707A2 (pt) | uso de uma quantidade eficaz de um inibidor de quinase tor, método para melhorar os critérios de avaliação, método para a inibição da fosforilação, método para a inibição da atividade de proteína, método para a medição da inibição da fosforilação, kit | |
| CN108366997A (zh) | 治疗痛觉过敏的方法 | |
| US20220202798A1 (en) | Use of pridopidine for the treatment of fragile x syndrome | |
| US20200054622A1 (en) | Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors | |
| CN116075302A (zh) | GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法 | |
| AU2011323899A1 (en) | Methods of treatment and/or prevention of scleroderma, UV injury or sunburn, formation of scars or keloids by using haloaryl substituted Aminopurines | |
| BR112020011345A2 (pt) | tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas | |
| JP2019516696A (ja) | 純粋な５−ｈｔ６受容体アンタゴニストのｎｍｄａ受容体アンタゴニストとの組合せ | |
| BR112021004938A2 (pt) | métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3 | |
| CN113924087A (zh) | 血清素4受体激动剂对抗应激的预防功效 | |
| EA041892B1 (ru) | Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов | |
| RU2799049C2 (ru) | Способы лечения изменений поведения | |
| TW201035081A (en) | Novel pharmaceutical composition for treatment of schizophrenia | |
| JP6738797B2 (ja) | レット症候群治療薬 | |
| JP2017514891A (ja) | 化学的に誘発された神経障害及びその症状の予防及び／または治療のための中枢作用性アセチルコリンエステラーゼ阻害剤、ならびに対応する組成物、使用、方法、及びキット | |
| WO2022173334A2 (en) | Methods, compositions and compounds for treating age-related diseases and conditions | |
| TW201929850A (zh) | 醫藥組成物於製備預防或治療不正常乙型-澱粉樣蛋白聚集類疾病之藥物上之用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |